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Experimental and Clinical Basis
for the Use of Statins in Patients With
Ischemic and Nonischemic Cardiomyopathy
Kumudha Ramasubbu, MD,* Jerry Estep, MD,* Donna L. White, PHD, MPH,†
Anita Deswal, MD, MPH,*†‡ Douglas L. Mann, MD*
Houston, Texas
Over the past 2 decades our understanding of the pathologic mechanisms that lead to heart failure (HF) has
evolved from simplistic hemodynamic models to more complex models that have implicated neurohormonal
activation and adverse cardiac remodeling as important mechanisms of disease progression. 3-Hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors (statins) have become a standard part of the armamentarium in
the prevention and treatment of coronary artery disease. Apart from their lipid-lowering capabilities, statins
seem to have non–lipid-lowering effects that impact neurohormonal activation and cardiac remodeling. This
review will examine the potential benefits of statins in HF patients with ischemic and nonischemic cardiomyopa-
thy as well as potential concerns regarding the use of statins in these patients. (J Am Coll Cardiol 2008;51:
415–26) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.10.009i
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dtatins lower plasma cholesterol by inhibiting 3-hydroxy-3-
ethylglutaryl coenzyme A (HMG-CoA) reductase, the
ate-limiting enzyme in the mevalonate pathway that is
esponsible for cholesterol synthesis. As illustrated in
igure 1, important intermediate products in the meval-
nate pathway include the isoprenoids, farnesyl pyrophos-
hate, and geranylgeranyl pyrophosphate (1,2). These in-
ermediate products lead to activation of various
ownstream intracellular signaling molecules by prenylation
f the guanosine triphosphate-binding proteins Rho, Ras,
nd Rac. The Rho signal transduction pathway is involved
n the activation of inflammatory cytokines and chemokines.
t also plays an important role in the formation and
aintenance of the actin cytoskeleton and thereby affects
ntracellular transport, messenger ribonucleic acid (mRNA)
tability, and gene transcription (3–5). The Ras proteins are
esponsible for cell proliferation and hypertrophy, and the
ac proteins are involved in the production of reactive
xygen species (5). Thus, inhibition of HMG-CoA reduc-
ase leads to a decrease in farnesylated and geranylgerany-
ated proteins and a subsequent dose-dependent reduction
rom the *Section of Cardiology and the Winters Center for Heart Failure Research,
epartment of Medicine, Baylor College of Medicine and The Texas Heart Institute
t St. Luke’s Episcopal Hospital, Houston, Texas; †Houston Center for Quality of
are and Utilization Studies, Houston, Texas; and the ‡Section of Cardiology,
ichael E. DeBakey VA Medical Center, Houston, Texas.h
Manuscript received July 2, 2007; revised manuscript received October 1, 2007,
ccepted October 2, 2007.n the downstream signaling pathways mediated by Rho,
as, and Rac (6).
eneficial effects of statins. ANT I - I N F LAMMATORY
FFECTS. It is now well accepted that the syndrome of
eart failure (HF) is associated with systemic inflamma-
ion characterized by increased activation of proinflam-
atory cytokines, cardiac auto-antibodies, cell adhesion
olecules, and the complement system. In fact, elevated
eve l s o f pro inflammatory markers inc lud ing
nterleukin-6, tumor necrosis factor, and C-reactive pro-
ein predict increased cardiovascular morbidity and mor-
ality in patients with HF (7–9). By decreasing the
roduction of farnesylated and geranylgeranylated pro-
eins, statins reduce the activation of the transcription
actor nuclear factor kappa-B, which plays an important
ole in regulating genes encoding proinflammatory cyto-
ines and adhesion molecules (3).
The reduction of inflammatory cytokines by statins has
een convincingly demonstrated in clinical studies. Sev-
ral small, prospective studies evaluated the effect of
tatin treatment on inflammatory markers in patients
ith left ventricular (LV) systolic dysfunction and New
ork Heart Association (NYHA) functional class II to
V HF symptoms (10 –14). Most of these trials noted a
ignificant decrease in concentrations of inflammatory
arkers after treatment with a statin for 16 weeks to 12
onths in patients with ischemic and nonischemic car-
iomyopathy. In contrast, 2 recent studies showed that
igh-dose atorvastatin and high-dose rosuvastatin were
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Statins and Cardiomyopathy January 29, 2008:415–26safe but had no effect on in-
flammatory biomarkers (10,15).
Potential explanations are the
type of statin used (with possi-
ble inherent differences in pleio-
tropic effects), dose of statin used
(both studies used very high
doses), and differences in back-
ground HF therapy. Moreover,
both studies enrolled patients
with relatively mild HF (NYHA
functional class I to III), who
likely had minimal activation of
neurohormonal and inflamma-
tory systems. Therefore, one
would not have expected to ob-
serve striking changes in the bi-
omarkers after statin treatment.
In inflammatory states, en-
dothelial cells and leukocytes
increase their expression of
adhesion molecules, thereby
triggering the migration of leu-
kocytes and further promoting
inflammation (16). Statins have
been demonstrated to inhibit
expression of intercellular ad-
hesion molecule-1 in in vitro
odels and significantly decrease vascular cell adhesion
olecule-1 levels in HF patients (13,17). Moreover,
Figure 1 Cholesterol Biosynthesis and the Beneficial and Adve
Beneficial (gray background) and adverse (checkered background) downstream effec
methylglutaryl coenzyme A; LPS  lipopolysaccharide; NAD(P)H  nicotinamide adenin
PP  pyrophosphate; tRNA  transfer ribonucleic acid.
Abbreviations
and Acronyms
CI  confidence interval
CoQ10  coenzyme Q10
eNOS  endothelial nitric
oxide synthase
EPC  endothelial
progenitor cell
HF  heart failure
HMG-CoA  3-hydroxy-3-
methylglutaryl coenzyme A
HR  hazard ratio
LV  left ventricular
LVEDD  left ventricular
end-diastolic dimension
LVEF  left ventricular
ejection fraction
NADPH  nicotinamide
adenine dinucleotide
phosphate
NO  nitric oxide
NYHA  New York Heart
Association
PI3K/Akt 
phosphatidylinositol-3
kinase-Akttatins seem to have a direct effect on cellular components
f inflammation, insofar as they inhibit the expression
f major histocompatibility complex class II on endothe-
ial cells and monocytes, resulting in inhibition of T-cell
ctivation (18).
NTIOXIDANT EFFECTS. Several experimental and clinical
tudies have suggested a causal role of increased oxidative
tress in the development of HF and that oxidative stress
ight be an important determinant of prognosis (19,20).
he enzyme nicotinamide adenine dinucleotide phosphate
NADPH) oxidase is suspected to be 1 of the major sources
f reactive oxygen species in HF (21). As described previ-
usly, intermediate products of the mevalonate pathway
ead to activation of Rac1, a subunit of NADPH oxidase,
nd hence to the production of reactive oxygen species (5).
ccordingly, statins reduce oxidative stress by inhibiting
ADPH oxidase. In animal models, statins have been
hown to attenuate oxidative stress, prevent progression of
ardiac hypertrophy to HF, and improve LV function
22–25). In humans, Maack et al. (26) demonstrated in
atients with advanced HF that atorvastatin and pravastatin
ignificantly reduced NADPH oxidase activity and thus free
adical production, presumably via inhibition of Rac1-
uanosine triphosphatase activity.
NDOTHELIAL FUNCTION. The relationship between the
F syndrome and impaired endothelial function has been
hown repeatedly in experimental and clinical studies
27,28). Endothelial dysfunction is characterized by a re-
uction in endothelial cell-derived nitric oxide (NO), which
ownstream Effects of Statin Treatment
tatin treatment. eNOS  endothelial nitric oxide synthase; HMG-CoA  3-hydroxy-3-
cleotide phosphate; NFB  nuclear factor kappa B; PI3  phosphatidylinositol-3;rse D
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January 29, 2008:415–26 Statins and Cardiomyopathyeads to impaired vascular relaxation, platelet aggregation,
nd increased vascular smooth muscle cell proliferation and
igration (29). In patients with HF, endothelial dysfunc-
ion seems to contribute to exercise intolerance, impaired
yocardial perfusion, and LV remodeling (30,31).
It has been suggested that statins exert vasoprotective
ffects through cholesterol-dependent and -independent
echanisms. The latter involve enhanced NO production
ithin vascular endothelial cells via 2 proposed pathways.
he phosphatidylinositol-3 kinase-Akt (PI3K/Akt) path-
ay leads to phosphorylation and thus activation of endo-
helial NO synthase (eNOS), resulting in increased NO
roduction. Statins seem to increase eNOS activity via
ost-translational activation of the PI3K/Akt pathway
32,33). In addition, activation of a second pathway, the
MP-activated protein kinase pathway, results in enhanced
NOS mRNA stability (34,35). In several clinical HF
tudies, statins have been shown to upregulate eNOS
36–38). In HF patients, Tousoulis et al. (13) demonstrated
hat atorvastatin significantly improved forearm vasodilatory
esponse to reactive hyperemia, suggesting an improvement
n endothelial function.
FFECTS ON ANGIOGENESIS. Recent studies have demon-
trated that levels of circulating endothelial progenitor cells
EPCs) are increased in patients with HF. Although the
xact role of EPCs in the pathogenesis of HF is not clear,
levated EPC levels in patients with advanced HF have
een shown to independently predict cardiovascular mortal-
ty (39). The EPCs can transdifferentiate into myocardial
nd vascular cells and thus contribute significantly to neo-
ngiogenesis, endothelial repair, and possibly myocardial
emodeling (40). Statins increase the number of circulating
PCs (41). The proposed mechanism involves statin-
nduced inhibition of the mevalonate pathway, which leads
o activation of the PI3K/Akt pathway resulting in the
nduction of EPC differentiation, improved EPC survival by
nhibiting apoptosis (42), and vascular endothelial growth
actor–induced endothelial cell migration (43). No reports
o date, however, have demonstrated an association between
tatin therapy and neoangiogenesis in patients with HF, and
he clinical significance remains unknown. The risk of
eveloping cancer has been a concern with agents promot-
ng neoangiogenesis and has been much debated with statin
herapy. Although multiple prospective randomized trials
ave not shown any increased risk for cancer with statin
reatment, a recent analysis of 23 statin treatment trials
howed a significant inverse association between cancer
ncidence and achieved low-density lipoprotein (LDL) cho-
esterol levels. Whereas a causal relationship cannot be
nferred from this analysis, the potential role of statins in the
evelopment of cancer still remains to be clarified (44).
ARDIAC HYPERTROPHY AND LV REMODELING. Left ven-
ricular remodeling involves complex alterations in the
iology of the cardiac myocyte as well as in the extracellular
atrix (45). Ras, Rho, and Rac have been implicated in cromoting LV hypertrophy (5,46). Statins seem to decrease
yocyte hypertrophy and attenuate LV remodeling by
uppressing Ras, Rho, and Rac activity (47–50). In addition
o inhibiting myocyte hypertrophy, statins affect myocardial
brosis. Martin et al. (51) showed that atorvastatin signif-
cantly reduces collagen synthesis, alpha(I)-procollagen
RNA expression, and gene expression of the profibrotic
eptide connective tissue growth factor in cell cultures of rat
nd human cardiac fibroblasts. Additionally, in a rat model
f cardiac hypertrophy, treatment with pitavastatin led to a
ecrease in the expression of hypertrophic and profibrotic
enes that was accompanied by a significant decrease in
nterstitial fibrosis and collagen deposition. Interestingly,
tatin-treated rats also showed smaller left ventricular end-
iastolic dimension (LVEDD), higher LV fractional short-
ning, and improved survival compared with the untreated
ats (52). In a different rat model of HF, rosuvastatin
ignificantly decreased Rac-1 expression and significantly
mproved left ventricular ejection fraction (LVEF), cardiac
ypertrophy, and perivascular fibrosis (25).
In humans, in a prospective randomized study of 108
atients, those receiving atorvastatin had a significant de-
rease in LVEDD from 57.1 to 53.4 mm, whereas patients
n the placebo group experienced an increase in LVEDD
56.1 to 60.3 mm) over a 12-month period (11). In another
tudy, Node et al. (53) demonstrated a significant decrease
n LV end-systolic volume and a nonsignificant decrease in
VEDD in 51 patients with symptomatic nonischemic
ardiomyopathy treated with simvastatin for 14 weeks. In
ontrast, in the UNIVERSE (Rosuvastatin Impact on
entricular Remodelling Lipids and Cytokines) trial, treat-
ent with high-dose rosuvastatin (40 mg/day) did not
esult in a significant improvement in LVEF relative to
lacebo. Potential explanations for this discrepant finding
emain uncertain but might be the inclusion of nonischemic
s well as ischemic patients, background HF therapies, the
hort study duration, small sample size, and the fact that
here were improvements in LVEF in the placebo group as
ell as in the treatment group (14).
EUROHORMONAL ACTIVATION. Both the adrenergic and
enin-angiotensin systems are activated in the setting of HF,
nd the magnitude of activation correlates with the severity
f symptoms and prognosis in HF patients. Therapies
imed at attenuating these systems have resulted in signif-
cant clinical benefit in patients with HF. Statins have been
emonstrated to modulate neurohormonal activation. Ele-
ated cholesterol levels have been associated with overex-
ression of angiotensin II type 1 receptor (54). Treatment
ith statins, in turn, has been shown to decrease levels of
hese receptors, resulting in both decreased angiotensin
I-mediated vasoconstriction and enhanced response to
ngiotensin receptor blocker drugs (55–57). Furthermore,
tatins have been shown to inhibit vascular endothelial
rowth factor-induced upregulation of angiotensin-
onverting enzyme (58). In addition, statins have been
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Statins and Cardiomyopathy January 29, 2008:415–26emonstrated to reduce expression of the endothelin type
-receptor, as well as beta1-receptor–stimulated apoptosis
2,59). However, the clinical significance of these observa-
ions in HF patients remains to be elucidated.
UTONOMIC REGULATION. The severity of autonomic dys-
egulation in HF correlates with disease severity and has
een associated with adverse outcome in patients with HF
60,61). Statins have been proposed to modulate the auto-
omic nervous system by activating eNOS and increasing
O production. On the premise that NO has sympatho-
nhibitory properties, statins might thus lower sympathetic
utflow (62). In a recent report, Pliquett et al. (63) showed
hat pravastatin normalized sympathetic outflow and reflex
egulation in rabbits with HF. In humans, however, Bleske
t al. (10) demonstrated in a randomized, double-blind,
lacebo-controlled trial that high-dose atorvastatin therapy
80 mg/day) had no beneficial effect on heart rate variability
n patients with nonischemic cardiomyopathy. This study,
owever, was limited by a small sample size (15 patients).
oreover, 80% of the patients studied had mild HF
NYHA functional class II) and might not have had
ignificant autonomic dysfunction. In a separate study,
rtovec et al. (64) randomized 80 HF patients to atorva-
tatin or placebo. After 3 months, patients treated with
torvastatin had a significantly higher heart-rate variability,
ower QT variability, and shorter QTc interval, all indica-
ors of improved autonomic function.
OTENTIAL ANTI-ARRHYTHMIC EFFECTS. There is emerg-
ng evidence that statins might have beneficial effects on
trial and ventricular arrhythmias in HF patients. Analysis
f ADVANCEMENT, a multicenter registry of patients
ith LV systolic dysfunction, showed that the use of
ipid-lowering drugs was associated with a significant re-
uction in the prevalence of atrial fibrillation (65). Second-
ry analyses of the MADIT (Multicenter Automatic Defi-
rillator Implantation Trial)-II, which included patients
ith ischemic cardiomyopathy, showed that the cumulative
ate of defibrillation for ventricular arrhythmias or sudden
ardiac death was significantly reduced in patients with
igher statin usage (66). Given the high prevalence of
oronary artery disease in these studies, the likely mecha-
ism of arrhythmia reduction with statin therapy is plaque
tabilization and thus reduction of ischemia-related tachy-
rrhythmias. However, even in nonischemic cardiomyopa-
hy, a secondary analysis of the DEFINITE (Defibrillators
n Non-Ischemic Cardiomyopathy Treatment Evaluation)
rial demonstrated a significant reduction in mortality and in
rrhythmic sudden death in patients taking statins (67).
hese findings suggest that the statins’ nonlipid-lowering
ffects might play a role in decreasing arrhythmias.
Apart from anti-ischemic properties of statins, other
roposed mechanisms for the observed decreased incidence
f atrial and ventricular arrhythmias in patients taking
tatins include potential membrane-stabilizing properties,
mprovement in autonomic function, and anti-inflammatory iroperties. Furthermore, statins seem to improve LV func-
ion and prevent remodeling and might thereby influence
he generation of ventricular arrhythmias (68). More re-
ently, experimental data suggest that Rac1 guanosine
riphosphatase (GTPase) might contribute to the pathogen-
sis of atrial fibrillation (69). Statins, by inhibiting HMG-
oA reductase, suppress Rac activity and might thus atten-
ate arrhythmias.
In summary, statins seem to have pleiotropic effects that
ight be beneficial in HF. Moreover, the molecular effects
f statins seem to overlap those of currently accepted HF
herapies. Table 1 shows that statins also have several
roperties that are not shared by current medical therapies
or HF, suggesting that this class of drugs might provide
dded benefit for patients with HF.
otential deleterious effects of statins. Despite the mul-
iple beneficial properties attributed to statins, there is some
oncern that statins might have unfavorable effects in HF
atients. This concern stems largely from retrospective
tudies, which report that a lower total cholesterol is
ssociated with higher mortality in patients with advanced
F. However, it remains to be determined whether low
holesterol is the cause for increased mortality or merely a
eflection of more advanced disease. Three main hypotheses
ave been presented outlining pathways leading to poten-
ially harmful effects of statins.
HE ENDOTOXIN–LIPOPROTEIN HYPOTHESIS. Circulating
holesterol and triglyceride-rich lipoproteins have the ca-
acity to detoxify bacterial lipopolysaccharide (endotoxin),
hich stimulate the release of inflammatory cytokines in
atients with HF. On the basis of this, higher levels of
holesterol are believed to be beneficial in patients with HF,
ecause serum lipoproteins can bind and inactivate lipopoly-
accharide. Statin therapy might thus increase levels of
irculating endotoxin, leading to increased systemic inflam-
ation and disease progression (70).
HE UBIQUINONE HYPOTHESIS. Statins inhibit synthesis of
biquinone (coenzyme Q10 [CoQ10]), a downstream prod-
ct in the mevalonate pathway (Fig. 1). Ubiquinone is
resent in all cells and membranes and serves a central role
n the mitochondrial respiratory chain (71). Potential ad-
erse effects of CoQ10 reduction in the setting of HF are
ecreased electron transport via CoQ10 in the mitochon-
rial respiratory chain, leading to a reduction in adenosine
riphosphate production, and inhibition of the antioxidant
unction of CoQ10, leading to a reduction in cellular
rotection from free radical injury with subsequent aggra-
ation of HF (72). Statin-induced CoQ10 reduction is well
ocumented in both animal and human studies (73). How-
ver, no studies to date have demonstrated that statin-
nduced reduction in CoQ10 tissue levels leads to adverse
linical outcomes in subjects with HF.
HE SELENOPROTEIN HYPOTHESIS. Selenoproteins play an
mportant role in muscle metabolism (skeletal and cardiac).
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January 29, 2008:415–26 Statins and Cardiomyopathyelenoprotein dysfunction and selenium deficiency have
een associated with myopathies. By inhibiting the meval-
nate pathway, statins decrease isopentenyl-pyrophosphate,
hich is required in the activation of selenocysteine–transfer
NA (tRNA). Thus, statins decrease selenoprotein produc-
ion, which theoretically could cause both skeletal and
ardiac muscle myopathy (74).
linical Experience With Statins
everal retrospective analyses of clinical trials or observa-
ional databases have suggested that the use of statins in
atients with coronary artery disease has either decreased
he incidence of HF (75) or reduced mortality in patients
ith known HF (76). Smaller prospective trials assessing
he effects of statins on nonmortality clinical end points and
ther surrogate end points (echocardiographic parameters
nd biomarkers of inflammation) also support the beneficial
ffects of statins in HF (11–13,50,77,78).
etrospective trials. Most of the data evaluating the clin-
cal effect of statins in patients with HF have been garnered
rom retrospective analyses of clinical trial databases. All
tudies included patients with ischemic and nonischemic
ardiomyopathy; the majority of patients had coronary
rtery disease. Inclusion criteria for these studies were
ymptomatic HF, LV dysfunction, or both. The main
linical outcome variable for all the studies was mortality.
reatment with statins consistently resulted in a significant
ecrease in mortality across multiple trials enrolling large
umbers of patients. Given the high prevalence of ischemic
eart disease in these HF trials, as well as the known
alutary effects of statins on outcomes in coronary artery
isease, these findings are not surprising. Furthermore,
hese are retrospective studies with inherent biases and
onfounders (79,80). Interestingly, retrospective analyses of
rials enrolling patients with coronary artery disease but
ithout prior history of HF demonstrated a reduction in the
isk of development of HF and HF hospitalizations in
atients taking statins (75,81,82). However, because all
tudies evaluated patients with coronary artery disease, the
bserved reduction in HF could simply be due to a reduc-
ion in the occurrence of ischemia/myocardial infarction.
rospective trials. Very few prospective trials of statin
reatment in patients with HF have been published. Several
mall, placebo-controlled studies in patients with nonisch-
mic cardiomyopathy and symptomatic systolic HF showed
n improvement in symptoms in patients taking statins
53,77,78). The fact that the statin effect cannot be attrib-
ted to the lowering of cholesterol and reduction in isch-
mic events further emphasizes the role of pleiotropic effects
f statins in HF. More recently, a small prospective trial
andomized 110 patients with NYHA functional class III
F and EF 30% to either atorvastatin 10 mg/day or no
tatin. Approximately 60% of the patients had ischemic
ardiomyopathy. At 1 year follow-up, a significantly lowermortality rate was noted in patients taking statins (16%T S B A A A D D C 
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Statins and Cardiomyopathy January 29, 2008:415–26ersus 36% respectively, p  0.017), which appeared to be
riven by a decrease in the rate of sudden cardiac death (83).
The largest prospective randomized trial to date,
ORONA (Controlled Rosuvastatin Multinational Trial
n Heart Failure), randomized 5,011 patients (60 years)
ith NYHA functional class II to IV heart failure of
schemic etiology to 10 mg rosuvastatin versus placebo (84).
n this trial, treatment with rosuvastatin did not confer a
ignificant benefit with respect to the primary end point
HR 0.92 [95% CI 0.83 to 1.02]; p  0.12), which was a
omposite of death from cardiovascular causes, nonfatal
yocardial infarction or nonfatal stroke, nor several second-
ry endpoints including all-cause mortality (Fig. 2) (HR
.95 [95% CI 0.86 to 1.05]; p  0.31) and coronary events
haracteristics of Studies Included for Meta-Analyses Evaluating th
Table 2 Characteristics of Studies Included for Meta-Analyses
Study (Ref. #)
(yr) Enrollment Dates Inclusion Criteria
Sam
(Statin/
Horwich et al.
(93) (2004)
1/2000–12/2002 EF 40% 551 (2
Ray et al. (96)
(2005)†
4/1995–12/2001 New HF hospital stay 28,828 (1
Krum et al. (95)
CIBIS II
(2006)†
Published 1999 EF 35%, NYHA
functional class
II–IV, diagnosis of
chronic HF
2,647 (2
Krum et al. (94)
Val-HEFT
(2006)†
Published 2001 Clinical findings of HF
(NYHA functional
class II–IV),
LVEF40%
5,010 (1
Foody et al. (79)
(2006)
4/1998–3/1999 and
7/2000–6/2001
Age 65 yrs,
discharge diagnosis
of CHF
54,960 (9
Anker et al. (88)
ELITE II (2006)
1997–1998 LV systolic dysfunction 3,132 (3
Anker et al. (90)
European study
(2006)
1992–2000 Diagnosis of HF 2,068 (7
Mozaffarian et al.
(80) PRAISE
(2004)
Published 1996 EF 30%, NYHA
functional class IIIB
or IV enrolled in
PRAISE
1,153 (1
Go et al. (92)
(2006)‡
1/1996–12/2004 Diagnosis of HF 24,598 (1
Folkeringa et al.
(91) (2006)†
1998–2000 First CHF admission 524 (1
Dickinson et al.
(97) (2007)
1997–2003 Class II–III HF 2,521 (9
Sola et al. (11)
(2005)§
Published 2005 Class II–III HF,
EF 35%
446 (2
Kjekshus (101)
CORONA
(2007)§
2003–2005 Class II–IV ischemic,
systolic HF
5,011 (2
Unable to extract exact number of patients in each group from information given. †Not included in
007), because these data were not available for intention-to-treat analysis in original publication.
re retrospective analyses.
CHF  congestive heart failure; EF  ejection fraction; HF  heart failure; LV  left ventricularHR 0.92 [95% CI 0.82 to 1.04]; p  0.18), despite a dignificant decrease in circulating levels of low-density
ipoprotein cholesterol and C-reactive protein (CRP).
hese results were surprising considering the known
alutary effects of statins on coronary events in patients
ith coronary artery disease. However, the rate of athero-
hrombotic events was relatively low in the CORONA
tudy, and the majority of deaths were due to sudden death
r worsening HF, which reflects the fact that the patient
opulation was comprised of patients with symptomatic HF
ather than symptomatic coronary artery disease. Thus, the
rimary composite end point of the CORONA study may
ot have captured the beneficial effects of rosuvastatin in
his elderly group of patients with advanced HF. And
ndeed, treatment with rosuvastatin resulted in a significant
fect of Statins in HF
ating the Effect of Statins in HF
e
atin) End Point Follow-Up Trial Setting
3) All-cause mortality
and urgent
transplantation
2 yrs University hospital HF
clinic
7,682) All-cause mortality 17–24 months Residents of Ontario,
insured in Ontario
Health plan
21) All-cause mortality 15 months Multicenter European
trial
,408) All-cause mortality 2 yrs Multicenter, multi-
national trial
5,797) All-cause mortality 3 yrs NHC project (CMC): 800
heart failure
discharges chosen
from each U.S. state
34) All-cause mortality 1 yr Multicenter trial
63) All-cause mortality 3 yrs Outpatients from
5 European centers
19) All-cause mortality 15 months Multicenter U.S. trial
11,950) All-cause mortality 2.4 yrs Kaiser Permanente of
Northern California
2) All-cause mortality Mean: 31  18 months Single center, university
hospital in Europe
56) All-cause mortality Median: 45.5 months Multicenter trial
1) All-cause mortality Mean: 24  5 months Multicenter, university
medical center
clinics
,497) All-cause mortality Median: 32.8 months Multicenter,
multinational trial
ed analysis. ‡Data for stratified analysis obtained by personal communication (Alan S. Go, January
ective trials (Sola et al. (11): nonrandomized, CORONA (101): randomized. The remaining studies
 New York Heart Association.e Ef
Evalu
ple Siz
No St
48/30
,146/2
26/2,4
,602/3
,163/4
98/2,7
05/1,3
34/1,0
2,648/
03/40
65/1,5
55/19
,514/2
stratifi
§Prospecrease in HF hospitalizations, which was a pre-specified
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January 29, 2008:415–26 Statins and Cardiomyopathyecondary end point in the CORONA study, thus refuting
peculation that treatment with statins might lead to wors-
ning HF. It also bears emphasis that there are differences
etween the CORONA study and previous prospective
tatin trials. For example, the CORONA study enrolled
lder patients with more advanced HF. Although statin use
n elderly patients with coronary artery disease has been
hown to be beneficial (85), elderly patients with coronary
rtery disease and HF may represent a sicker population
ith more comorbidities, in whom significant cholesterol
owering may no longer have a favorable impact on cardio-
ascular death because the atherosclerotic and/or myocardial
isease is simply too advanced to modify. This is supported
y the subgroup analysis demonstrating a trend towards
ontinued
Table 2 Continued
Male (%) Age, yrs Mean EF, %
419 (76%) 52 13 25 7
Statin: 53.4%;
no statin: 48.8%
76.5
2,132 (80.5%) Statin/bisoprolol: 58;
statin/placebo: 61;
no statin/bisoprolol: 61;
no statin/placebo: 61
Statin/bisoprolol: 26;
statin/placebo: 28;
no statin/bisoprolol: 27
no statin/placebo: 27
4,005 (79.9%) Statin: 63 (56–69);
no statin: 64 (56–72)
Valsartan: 26.6  7.3;
placebo: 26.9  7.0
22,869 (42%) 79.4 40: 48%; 40: 52%
2,170 (69.3%) 71.5 6.8 31.1 6.9
1,659 (80.2%) 61.7 0.3 30.1 0.3
876 (76%) Statin: 65.5  8.2;
no statin: 64.7  11.5
Statin: 22  6;
no statin: 21  6
14,890 (60.5%) Statin: 69.6  10.3;
no statin: 72.9  11.4
NR
Statin: 68 (66%);
no statin: 198 (49%)
Median 74 Statin: 42; no statin: 38
1,933 (77%) Statin: 61; no statin: 59 Statin: 25; no statin: 23
277 (62%) Statin: 55.4 6.4;
no statin: 53.8 5.7
Statin: 33 5;
no statin: 34 4
Statin: 1,921 (76%);
no statin: 1,910 (76%)
Statin: 73 7.1;
no statin: 73 7
Statin: 31 7;
no statin: 31 7mproved outcomes with rosuvastatin in younger patients tnd patients with higher blood pressure and lower brain
atriuretic peptide levels possibly reflecting a healthier
aseline status. Secondly, the CORONA and UNIVERSE
rials used rosuvastatin compared to previous clinical trials
hat employed more lipophilic statins (2), raising the ques-
ion of whether the effect of statins in HF can or should be
iewed as a class effect.
Several of the smaller, prospective clinical trials have also
emonstrated a favorable effect of statins on measures of
ystolic function. Treatment with simvastatin (53) and
torvastatin (78) demonstrated a significant improvement in
VEF after 14 weeks to 6 months. Similarly, Sola et al. (11)
eported a significant increase in LVEF (33% to 37%) in 46
atients treated with atorvastatin while the 43 patients in
Ischemic, n (%) Nonischemic, n (%)
Baseline Cholesterol,
mg/dl
248 (45%)* 138 (25%)* 170 57
* Not mentioned
1,561 (59%)* 966 (36.5%)* Not mentioned
65 (57%)
Statin: 1,308;
no statin: 1,557
2,145 (43%)
Statin: 293;
no statin: 1,851
Statin: 187.2 (164.0–
216.9); no statin:
206.1 (177.1–237.4)
,762 (57.8%)
Statin: 7,446;
no statin: 24,316
23,193 (42.2%)
Statin: 1,717;
no statin: 21,481
200: 77%
200–240: 15.4%
240: 7.6%
02 (73.5%)
Statin: 351;
no statin: 1,952
830 (26.5%)
Statin: 47;
no statin: 782
206.5 46.0
02 (58.1%)
Statin: 585;
no statin: 617
866 (41.9%)
Statin: 120; no statin: 746
206.9 1.5
3 (63.6%)
Statin: 111;
no statin: 622
420 (36.4%)
Statin: 23; no statin: 397
Statin: 225  52;
no statin: 199  49
19,705 (80.1%)* 4,893 (19.9%)* Statin: 220.3  47.5;
no statin: 207.8 44.4
193 (36%)* Not mentioned
10 (52%)
Statin: 743;
no statin: 567
1,211 (48%)
Statin: 222; no statin: 989
Not mentioned
6 (44%)
Statin: 107;
no statin: 88
250 (56%) Not mentioned
11 (100%)
Statin: 2,514;
no statin: 2,497
0 Statin: 209 43.3;
no statin: 208.741.3;
2,8
31
2,3
1,2
73
1,3
19
5,0he placebo group experienced a decline (from a baseline of
3
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Statins and Cardiomyopathy January 29, 2008:415–263% to 31%) over 12 months. In contrast, patients with HF
reated with rosuvastatin 40 mg showed no difference in LV
unction compared with the placebo group (14), and a
urther study with cerivastatin only showed a trend towards
ncreased LVEF by radionuclear ventriculography (77).
ossible explanations for these discrepant results include
hoice of statin, differences in statin dosage, and patient
election.
The data on the use of statins in patients with HF and
reserved systolic function is limited. Fukuta et al. (86)
erformed a prospective observational study in 137 patients
ith HF and LVEF50% for 21 12 months (86). These
uthors demonstrated that statin treatment was associated
ith a substantial improvement in survival, whereas treat-
ent with an angiotensin-converting enzyme inhibitor,
ngiotensin-receptor blocker, beta-blocker, or calcium
hannel blocker had no significant effect on survival. These
esults further support a potential niche for the use of statins
n HF patients.
eta-analysis. We performed a meta-analysis to obtain
better estimate of the magnitude of survival benefit with
tatins in HF and to better compare the effects of statins
n patients with HF of ischemic and nonischemic etiol-
gies. For this analysis, the medical literature was
earched using the following search terms: statins and
eart failure, HMG-CoA reductase inhibitors and heart
ailure, statins and systolic dysfunction. Trials were
ncluded in the meta-analysis if the primary focus was the
valuation of the effect of statins on mortality in patients
ith HF. Only trials that reported results as an HR were
Figure 2 Kaplan-Meier Estimates for Death
From Any Cause in the CORONA Trial
Adapted from Kjekshus et al. (84).ncluded. The following studies were excluded: non-nglish publications, abstracts, and evaluation of statins
n the prevention of HF.
For the meta-analysis, the effect measure of choice was
he HR and associated 95% CI. Heterogeneity was
valuated with Higgins I (87), and a random effects
eta-analysis was performed (88). The meta-analysis
esults are presented as forest plots with HRs and 95%
Is for all individual studies as well as the overall pooled
stimator. We employed Egger’s regression test to assess
f there was potential small study or publication bias (89).
inally, we performed a stratified meta-analysis to eval-
ate whether the overall effect of statin use on relative
isk of mortality differed among subgroups of HF pa-
ients (i.e., HF of ischemic and nonischemic etiology).
ll analyses were conducted using STATA 9.0 (Stata
orp., College Station, Texas).
Thirteen studies met the inclusion criteria for this
eta-analysis (Table 2) (79,80,84,85,90 –97), of which
1 were retrospective analyses and 2 were prospective
tudies. Overall, the pooled estimator suggested that
tatin use among HF patients conveys a significant 26%
ecreased relative risk of mortality (HR  0.74; 95% CI
.68 to 0.8) (Fig. 3). Eight of the 13 studies presented
Rs for HF of ischemic and nonischemic etiology
eparately, and these were used in a stratified analysis.
nterestingly, the result of the stratified analysis demon-
trated a similarly protective effect of statins among HF
atients regardless of etiology (HRischemic  0.73; 95%
I 0.65 to 0.82 vs. HRnonischemic  0.73; 95% CI 0.61 to
.87) (Fig. 4). Moreover, both the magnitude and preci-
ion of the observed statin benefit were similar in the
verall analysis as well as in the subgroup analysis. Of
ote, the improved mortality was seen when statins were
dded to currently recommended therapy for HF. The
ooled estimators were also calculated excluding the 2
rospective trials: no significant change was noted (over-
Figure 3 Mortality Among Patients With Heart Failure
Heart failure patients using statins (n  30,107);
heart failure patients not using statins (n  101,323).
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January 29, 2008:415–26 Statins and Cardiomyopathyll HR  0.72; 95% CI 0.66 to 0.78; HRischemic  0.69;
5% CI 0.60 to 0.78; HRnonischemic  0.73; 95% CI 0.61
o 0.87).
One limitation of the present meta-analysis is that the
ajority of included studies were retrospective, due to the
aucity of prospective data. Thus, the results of the
eta-analysis suffer from the shortcomings of retrospec-
ive studies, including different baseline characteristics
nd nonrandomization of treatment allocation. Secondly,
he heterogeneity concerns confronted in any meta-
nalysis also exist here, for example, variable length of
ollow-up, variable types of statins used, various dosages
f statins used, and lack of individual patient data.
espite these limitations, the results do show a signifi-
ant reduction in relative risk of mortality with use of
tatins among HF patients regardless of etiology.
onclusions: Statins in Perspective
n this review we have outlined the theoretical and
linical benefits of statins in patients with HF. Statins
ave several properties that are not shared by current
edical therapies for HF, suggesting that this class of
rugs might result in added benefit for patients receiving
urrent HF therapies. Further, the results of our meta-
nalysis suggests that statin therapy leads to a 26%
eduction in the risk of mortality in HF patients. More-
ver, the magnitude of benefit of statins in this meta-
nalysis was similar in patients with ischemic and non-
schemic cardiomyopathy. Although the meta-analysis is
ased on retrospective, nonrandomized studies performed
n patients receiving various background therapies, the
eduction in mortality risk for statins is similar to that
Figure 4 Mortality Among Patients With Heart Failure: Ischemi
(A) Adjusted mortality among patients with ischemic etiology (n  62,273) using s
(B) Mortality among patients with heart failure of nonischemic etiology (n  31,55eported in clinical trials with angiotensin-convertingnzyme inhibitors (18% to 44%) and beta-blocker drugs
23% to 35%) (98 –102). As previously noted, the results
f the meta-analysis are in disagreement with the results
f the prospective CORONA study, which showed a
onsignificant (p  0.31) 5% decrease in all-cause
ortality in elderly patients with moderate to advanced
eart failure. Whether the negative results of the
ORONA study represent patient selection, the hydro-
hilic properties of rosuvastatin, or true lack of treatment
enefit of statins in HF cannot be addressed at present.
he ongoing prospective trial GISSI-HF (103), which is
nrolling patients with ischemic and nonischemic HF,
hould provide additional insight into whether statins
ill add to currently recommended HF therapy. That
aid, given the conflicting results of the trials previously
iscussed, it is premature to recommend the routine use
f statins for the treatment of patients with HF outside of
urrent practice guidelines for the treatment of coronary
rtery disease.
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